Levomilnacipran (Fetzima™) for the treatment of major depressive disorder

2014 ◽  
Vol 4 (1) ◽  
pp. 27-30
Author(s):  
Clint Ross
Keyword(s):  
United States ◽  
Major Depressive Disorder ◽  
Side Effects ◽  
Depressive Disorder ◽  
Clinical Studies ◽  
Antidepressant Medication ◽  
The United States ◽  
Major Depressive ◽  
United States Food ◽  
States Food

Levomilnacipran (Fetzima™) was approved by the United States Food and Drug Administration (FDA) in July 2013 for the treatment of Major Depressive Disorder (MDD) in adults. Levomilnacipran is the (1S,2R) enantiomer of racemic milnacipran and represents one of the newest medications designed and marketed as an enantiomer of an already approved medication with hopes of improving efficacy and limiting side effects. This article reviews the evidence supporting the use of milnacipran for MDD, examines the clinical studies behind levomilnacipran's approval, and discusses practical considerations regarding the use of this new antidepressant medication.

Use of a Second Generation Antipsychotic among Patients Diagnosed with Major Depressive Disorder in the United States

2012 ◽  
Vol 26 (4) ◽  
pp. 235-241
Author(s):  
David A. Sclar ◽  
Linda M. Robison ◽  
Lawrence J. Cohen ◽  
Kimberly K. Laubmeier ◽  
Iftekhar D. Kalsekar ◽  
...  
Keyword(s):  
United States ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Second Generation ◽  
The United States ◽  
Major Depressive ◽  
Second Generation Antipsychotic

scholarly journals Higher dose weekly fluoxetine in hemodialysis patients: A case series report

2020 ◽  
Vol 56 (1) ◽  
pp. 3-13
Author(s):  
Kelley M Kauffman ◽  
Jacqueline Dolata ◽  
Maria Figueroa ◽  
Douglas Gunzler ◽  
Anne Huml ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Side Effects ◽  
Depressive Disorder ◽  
Case Series ◽  
Antidepressant Medication ◽  
Hemodialysis Patients ◽  
Future Research ◽  
Major Depressive ◽  
Patient Health ◽  
Case Series Report

Objective The antidepressant medication fluoxetine at 90 mg dosed weekly is as effective and safe as standard formulation fluoxetine 20 mg dosed daily in patients with major depressive disorder. Weekly fluoxetine has not been well studied in hemodialysis patients, and doses beyond 90 mg/week have not been described in this population. This case series, derived from a larger study on depression in hemodialysis patients, describes the use of weekly fluoxetine at dosages beyond 90 mg/week. Method Hemodialysis patients with depressive symptom severity scored ≥10 on the 9-item Patient Health Questionnaire and major depressive disorder confirmed with Mini International Neuropsychiatric Interview were initially prescribed daily fluoxetine for two weeks and then transitioned to weekly fluoxetine. Dosage titration was made at the discretion of the prescribing clinician. Fluoxetine was continued for a total of 12 weeks. Results Four women, aged 24 to 65 years, on hemodialysis for 1 to 18 years, were started on weekly fluoxetine that was increased over several weeks up to 180 mg. Side effects included restlessness, dry mouth, sedation, and lightheadedness. Two patients ultimately had their weekly fluoxetine decreased back to 90 mg. However, all four continued weekly fluoxetine as part of poststudy aftercare and no longer met diagnostic criteria for major depressive disorder, current episode. Conclusions Weekly fluoxetine at doses of 180 mg may be a reasonable treatment consideration for hemodialysis patients who have partial or insufficient antidepressant response. Side effects may limit tolerance of the 180 mg dose in some individuals. Future research should investigate longer term health outcomes of weekly fluoxetine in this population.

Major Depressive Disorder and Insulin Resistance in Nondiabetic Young Adults in the United States: The National Health and Nutrition Examination Survey, 1999-2002

2010 ◽  
Vol 13 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Qiuhua Shen ◽  
Sandra Bergquist-Beringer ◽  
Valmi D. Sousa
Keyword(s):  
United States ◽  
Insulin Resistance ◽  
Young Adults ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
National Health ◽  
The United States ◽  
Nutrition Examination Survey ◽  
Major Depressive ◽  
Health And Nutrition

Objective: The association between depression and insulin resistance has been evaluated in previous studies with conflicting results. This study aimed to explore the relationship between major depressive disorder (MDD) and insulin resistance among nondiabetic young adult men and women in the United States. Method: Analyses of cross-sectional data from the National Health and Nutrition Examination Survey (NHANES), 1999—2002, were conducted. The nationally representative sample consisted of 279 men and 358 women aged 20—39 years. MDD was determined by the WHO Composite International Diagnostic Interview (CIDI). Insulin resistance was measured by the homeostasis model assessment for insulin resistance. Results: Of 637 subjects, 16 men and 18 women had MDD (weighted percentage = 6.6%, SE = 1.2). Using logistic regression, no significant association was found between MDD and insulin resistance among the nondiabetic young adults in bivariate analysis (β = -0.01, OR = 0.99, 95% CI = [0.38, 2.57], p = .98). A significant interaction effect between gender and MDD was observed. For men, MDD was negatively associated with insulin resistance after adjusting for age, race/ethnicity, waist circumference, smoking status, systolic blood pressure and triglyceride level (β = -2.12, OR = 0.12, 95% CI = [0.02, 0.62], p = .01). No significant association between MDD and insulin resistance among women was found (β = 0.61, OR = 1.84, 95% CI = [0.47, 7.14], p = .38). Conclusions: Overall findings suggest there is no significant association between MDD and insulin resistance among nondiabetic young adults aged 20—39 years. However, gender differences in this relationship were noted.

scholarly journals PMH3 Acne Drug Therapy and the Development of Comorbid Major Depressive Disorder in the United States

2012 ◽  
Vol 15 (4) ◽  
pp. A81
Author(s):  
H.C. Lin ◽  
R.P. Clodfelter ◽  
C.H. Lee ◽  
R. Balkrishnan ◽  
S.R. Feldman
Keyword(s):  
United States ◽  
Major Depressive Disorder ◽  
Drug Therapy ◽  
Depressive Disorder ◽  
The United States ◽  
Major Depressive

Anxiety Disorders

2021 ◽  
pp. 326-332
Author(s):  
Ahmed T. Makhlouf
Keyword(s):  
United States ◽  
Major Depressive Disorder ◽  
Anxiety Disorder ◽  
Depressive Disorder ◽  
Anxiety Disorders ◽  
The United States ◽  
Major Depressive ◽  
Neurologic Disorders ◽  
Disability Adjusted Life ◽  
Life Years

Anxiety disorders are the most common psychiatric syndromes in the United States. About 29% of adults will receive a diagnosis of an anxiety disorder during their lifetime, and almost one-fifth of adults have symptoms of anxiety in any given year. Globally, anxiety disorders are responsible for 10% of the disability-adjusted life years for all psychiatric and neurologic disorders, second only to major depressive disorder.

PMH9 Economic Burden of Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the United States

2021 ◽  
Vol 24 ◽  
pp. S129-S130
Author(s):  
M. Zhdanava ◽  
J. Voelker ◽  
D. Pilon ◽  
J.J. Sheehan ◽  
L. Morrison ◽  
...  
Keyword(s):  
United States ◽  
Major Depressive Disorder ◽  
Suicidal Ideation ◽  
Depressive Disorder ◽  
Economic Burden ◽  
The United States ◽  
Major Depressive
Sign in / Sign up

Export Citation Format

Share Document